Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors.

Dorien Laenens Yu-Ling Yu Beatrice Santens Johanna E J Jacobs Benoit Beuselinck Oliver Bechter Els Wauters Jan A StaessenStefan JanssensLucas N L Van Aelst

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Cardiovascular events during and after ICI treatment are more common than currently appreciated. Patients at risk are those with a history of cardiovascular disease. Compared with matched cancer and population controls, MACE incidence rates are significantly higher, suggesting a potential harmful effect of ICI treatment besides the underlying risk.

Keyphrases

cardiovascular events
cardiovascular disease
coronary artery disease
end stage renal disease
risk factors
newly diagnosed
chronic kidney disease
type diabetes
peritoneal dialysis
metabolic syndrome
risk assessment
combination therapy
patient reported outcomes